Activity-based chemical proteomics accelerates inhibitor development for deubiquitylating enzymes.

Converting lead compounds into drug candidates is a crucial step in drug development, requiring early assessment of potency, selectivity, and off-target effects. We have utilized activity-based chemical proteomics to determine the potency and selectivity of deubiquitylating enzyme (DUB) inhibitors i...

תיאור מלא

מידע ביבליוגרפי
Main Authors: Altun, M, Kramer, H, Willems, L, McDermott, J, Leach, C, Goldenberg, S, Kumar, K, Konietzny, R, Fischer, R, Kogan, E, Mackeen, M, McGouran, J, Khoronenkova, S, Parsons, J, Dianov, G, Nicholson, B, Kessler, B
פורמט: Journal article
שפה:English
יצא לאור: 2011

פריטים דומים